Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262941 | 1.00 | HSD17B10 (0.38) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL18173867 | 1.00 | HSD17B10 (0.38) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL1438928 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL4912304 | 0.92 | — | — | |
| SCHEMBL81956 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL6666413 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL14950228 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL6664456 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL20534906 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL25495618 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169618-B2 | Magnetic particles and methods of producing coated magnetic particles | SKOLD TECHNOLOGY (US) | 2007-01-30 | — | — | US | claimed |
| US-20020000398-A1 | Magnetic particles and methods of producing coated magnetic particles | SKOLD TECHNOLOGY | 2002-01-03 | — | — | US | claimed |
| WO-2025137541-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12239639-B2 | Cytotoxic actin-targeting compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2025-03-04 | — | — | US | disclosed |
| CN-114174299-B | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligand and methods of use | 百济神州有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| CN-116490184-A | Compounds for inhibiting EGFR mutant cancers and pharmaceutical uses thereof | J2H生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20050192430-A1 | Linker arms for nanocrystals and compounds thereof | ROSENTHAL SANDRA J (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005010481-A2 | PREPARATION AND USE OF GOLD GLYCONANOPARTICLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030129590-A1 | Linker arms for nanocrystals and compounds thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-10 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001090716-A2 | LINKER ARMS FOR NANOCRYSTALS AND COMPOUNDS THEREOF | VANDERBILT UNIVERSITY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0048705-B1 | 2-(4-(DIPHENYLMETHYLENE)-1-PIPERIDINYL)-ACETIC ACIDS AND THEIR AMIDES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | U C B, S.A. (BE) | 1984-07-11 | — | — | EP | disclosed |
| US-4443460-A | ANTIALLERGENS, ANTIHISTAMINES, ANTISPASMODICS, BRONCHODILATORS | UCB, SOCIETE ANONYME (BE) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129590-A1 | Linker arms for nanocrystals and compounds thereof | SCO2, NCL, NCAPH | HSD17B10 2214/4885BLM 3756/4885PMP22 2543/4885 |
| US-12239639-B2 | Cytotoxic actin-targeting compounds | ACTB, ACTR2, MYC | HSD17B10 2938/4885BLM 3046/4885PMP22 4509/4885 |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | HSD17B10 2789/4885BLM 3073/4885PMP22 4563/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | HSD17B10 2241/4885BLM 4257/4885PMP22 4128/4885 |
| US-20050192430-A1 | Linker arms for nanocrystals and compounds thereof | NCL, CHN2, SCO2 | HSD17B10 3601/4885BLM 4194/4885PMP22 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.